



Europäisches Patentamt
European Patent Office
Office européen des brevets

⑪ Publication number:

0 240 228
B1

⑫

EUROPEAN PATENT SPECIFICATION

⑯ Date of publication of the patent specification:
07.11.90

⑮ Int. Cl. 5: **C07D 281/16, A61K 31/55**
// **C07C323/62**

⑯ Application number: **87302539.9**

⑯ Date of filing: **24.03.87**

⑯ **Thiazepine compounds.**

⑯ Priority: **27.03.86 GB 8607684**

⑯ Proprietor: **ICI AMERICAS INC., Concord Pike & New Murphy Road, Wilmington Delaware 19897(US)**

⑯ Date of publication of application:
07.10.87 Bulletin 87/41

⑯ Inventor: **Warawa, Edward John, 155 Oldbury Drive, Wilmington Delaware 19808(US)**
Inventor: **Migler, Bernard Martin, 1405 Autumn Lane, Cherry Hill New Jersey 08003(US)**

⑯ Publication of the grant of the patent:
07.11.90 Bulletin 90/45

⑯ Representative: **Mack, John Richard et al, Imperial Chemical Industries PLC Legal Department: Patents PO Box 6 Bessemer Road, Welwyn Garden City Hertfordshire AL7 1HD(GB)**

⑯ Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

⑯ References cited:
BE-A-721 822
DE-A-1 620 188
US-A-3 539 573
US-A-4 097 597

B1
Chemical Abstracts, vol 83, no 11. 15 September 1980,
page 727, column 1, abstract no 114451y, Columbus,
Ohio, US; Anon 'Piperazinylidbenzazepine'

EP 240 228 B1
The file contains technical information submitted after
the application was filed and not included in this
specification

EP Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description**SUMMARY AND BACKGROUND OF THE INVENTION**

5 This invention concerns a novel dibenzothiazepine compound useful for its antidopaminergic activity, for example, as an antipsychotic or neuroleptic.

10 Previous attempts at finding compounds useful in a variety of applications have included U.S. Patent No. 3,539,573 to Schmutz et al. which discloses selected dibenzothiazepines and dibenzodiazepines as being useful for a variety of medical conditions including as neuroleptic-antidepressants, or neuroleptics. U.S. Patent No. 3,389,139 to Schmutz et al. teaches compounds based on 6-basic substituted morphanthydines as neuroleptics, neuroleptics and analgesics, with selected compounds being useful for treating psychotic conditions. U.S. Patent 4,097,597 to Horrom et al. discloses dibenzodiazepine derivatives useful as antischizophrenics.

15 A compound of the following formula I
(Formula set out on pages following Examples) I

in which X may be as shown in formula Ia

(Formula set out on pages following Examples) Ia

and R may be $(CH_2CH_2O)_2H$, has been anonymously disclosed in *Res. Disc.* (1980), 192: 158-9.

20 Compounds used as antipsychotics and neuroleptics have, however, been plagued by the problems of undesired side effects. Such side effects include acute dyskinesias, acute dystonias, motor restlessness, pseudo-Parkinsonism and tardive dyskinesias (TD). Acute syndromes usually have an early onset, for example, 1 to 5 days for acute dystonias and dyskinesias, and may include torsion spasms, muscle spasms and dystonia of the face, neck or back with protrusion of the tongue and tonic spasms of the limbs (dyskinesia). Tardive dyskinesia has a time of maximal risk after months or years of treatment. TD's 25 comprise oral-facial dyskinesia, lingual-facial-buccal-cervical dystonias sometimes with involvement of the trunk and extremities. TD's also include repetitive stereotypical movements of the face, tongue and limb such as sucking and smacking of the lips, lateral jaw movements and protrusions of the tongue. When the antipsychotic drug treatment is stopped the symptoms continue, often for months or years. These involuntary movements constitute the most undesirable side effect of antipsychotic drug treatment. 30 For example, the percentage of patients that develop TD has been variously reported to be as high as 20 percent. Thus, there still remains a need for compounds which exhibit antidopaminergic activity without the side effects heretofore experienced with previous compounds.

DESCRIPTION OF THE INVENTION

35 This invention is a compound of formula II:
(Formula set out on pages following Examples) II

40 and the salts e.g. pharmaceutically acceptable salts thereof. Such a compound is useful because of its antidopaminergic activity, for example, as an antipsychotic agent or as a treatment for hyperactivity. Such a compound is of even greater interest in that it may be used as an antipsychotic agent with a substantial reduction in the potential to cause side effects such as acute dystonia, acute dyskinesia, pseudo-Parkinsonism as well as tardive dyskinesia which may result from the use of other antipsychotics or 45 neuroleptics.

The compound of formula II may be made by a variety of methods including taking the lactam of formula III:

(Formula set out on pages following Examples) III

50 which may be prepared by methods well known in the literature, for example, as described by J. Schmutz et al. *Helv. Chim. Acta*, 48:336 (1965), and treating the lactam of formula III with phosphorus oxychloride ($POCl_3$) to generate the imino chloride of formula IV:

(Formula set out on pages following Examples) IV

55 The imino chloride of formula IV may be generated with other agents such as thionyl chloride or phosphorus pentachloride. The imino chloride is then reacted with 1-hydroxyethoxyethylpiperazine of formula V:

(Formula set out on pages following Examples) V

to give the compound of formula II.

60 Alternatively, one may convert the lactam of formula III into a thiolactam of formula VI:

(Formula set out on pages following Examples) VI

65 by, for example, reacting the lactam of formula III with a polysulfur compound such as phosphorous pentasulfide or 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide (Lawesson's Reagent, obtained from Aldrich).

The lactam of formula VI may then be converted into a thioether of formula VII:

(Formula set out on pages following Examples) VII

where R¹ is chosen such that S-R¹ is a leaving group, for example, R¹ may be (1-3C)alkyl, for example, methyl, by alkylation with an alkyl iodide, for example, methyl iodide. The piperazine of formula V is then reacted with the thioether of formula VII to give the compound of formula II.

A preferred way of making the compound of formula II is as follows. A compound of formula XII: (Formula set out on pages following Examples) XII is reacted with a compound of formula XIII: (Formula set out on pages following Examples) XIII

5 (in which Z is an atom or group removable as an anion) and, whereafter, when the compound of formula II is obtained as a base and a salt is required, reacting said compound of formula II obtained in the form of a base with an acid to afford a salt and when the compound of formula II is obtained as a salt and a base is required, neutralizing said compound of formula II obtained in the form of a salt to afford the said base.

10 A compound of formula XIII is advantageously used in which Z represents a mesyloxy or tosyloxy group, but Z is preferably halogen, Z most preferably represents a chlorine atom.

15 The reaction is conveniently carried out in the presence of a solvent, preferably a polar organic solvent, more preferably an alcohol, especially a (1-6C)alkanol, for example, methanol, ethanol, propanol, butanol, pentanol, hexanol and isomers thereof especially n-propanol. Other convenient solvents include aprotic solvents such as for example dimethylformamide or N-methyl pyrrolidone. If desired, an appropriate mixture of polar organic and aprotic solvents may be used.

20 If desired the compound of formula XII may be employed in the form of a salt, but where such a salt is used it is neutralized to afford the corresponding free base prior to reaction with the compound of formula XIII, for example, by *in situ* neutralization. Such neutralization is advantageously conducted in the presence of a basic substance, preferably an alkali metal carbonate or an alkaline earth metal carbonate, more preferably sodium or potassium carbonate.

25 Additionally an alkali metal halide, advantageously in a catalytic amount, may optionally be added to the reaction mixture. Sodium iodide is a preferred alkali metal halide. The effect of this addition is to convert Z in formula XIII to a halogen, preferably iodine, whereby the reaction of the compound of formula XII with the compound of formula XIII may be promoted.

30 The reaction is conveniently performed at ambient temperature or at an elevated temperature, preferably at a temperature between ambient and the reflux temperature of the reaction mixture, more preferably at the reflux temperature, and advantageously the reaction is carried out for an extended period of time, preferably 15 to 30 hours, more preferably about 24 hours.

35 The salts of the compound of formula II prepared according to the process of the present invention are preferably the pharmaceutically acceptable salts, but other salts may also be prepared. Such other salts may, for example, find use in the preparation of the compound of formula II and the pharmaceutically acceptable salts thereof. Convenient salts may be selected from those pharmaceutically acceptable salts known in the art. These may be obtained, for example, by reacting the compound of formula II with a convenient acid, such as for example, hydrochloric acid, maleic acid, fumaric acid, citric acid, phosphoric acid, methane sulfonic acid, and sulfuric acid. A preferred salt is the hemi-fumarate salt.

40 The compound of formula XII is preferably prepared by the reaction of an 11-substituted-dibenzo-[b,f][1,4]thiazepine of the formula XIV:

(Formula set out on pages following Examples) XIV

45 in which the substituent Y represent an atom (or a group removable as an anion), with piperazine. A compound of formula XIV may, for example, be used in which Y represents an alkoxy, alkylthio or sulfonate group. Thus, Y may, for example, represent (1-6C)-alkoxy, preferably methoxy or ethoxy, or (1-6C)-alkylthio, preferably methylthio or ethylthio, or Y may represent a tosyloxy group. Preferably Y represents a halogen atom, for example, bromine but especially chlorine. The reaction is conveniently performed at ambient temperature or at an elevated temperature, preferably at a temperature between ambient and the reflux temperature of the reaction mixture, more preferably at the reflux temperature, and advantageously the reaction is carried out in the presence of an inert organic solvent, preferably an aromatic hydrocarbon solvent, such as, for example, xylene or toluene. The reaction is conveniently performed for 2 to 15 hours, preferably 3 to 10 hours, more preferably about 5 hours.

50 The compounds of formula XIV may, for example, be prepared by methods analogous to those known in the art or, where Y represents halogen, preferably by reacting dibenzo[b,f][1,4]-thiazepine-11(10H)-one of formula XV:

(Formula set out on pages following Examples) XV

55 with a halogenating agent, preferably a phosphorous pentahalide or oxyhalide (POHal₃). The above halide is selected, for example, from chlorine or bromine, especially chlorine. Where it is desired to prepare a compound of formula XIV in which Y represents a chlorine atom, a preferred halogenating agent is phosphorous oxychloride (POCl₃). Where it is desired to prepare a compound of formula XIV in which Y represents a bromine atom, a preferred halogenating agent is phosphorous pentabromide. The reaction may advantageously be carried out in the presence of an N,N-disubstituted aniline, preferably N,N-di[1-6C]-alkyl) substituted aniline, more preferably an N,N-dimethylaniline. The reaction is advantageously effected at an elevated temperature, preferably at the reflux temperature of the reaction mixture, conveniently for between 3 to 15 hours, preferably 4 to 10 hours, more preferably 6 hours.

60 The compound of formula XV may, for example, be prepared according to methods known in the art, for example, by the method disclosed by J. Schmutze et al. *Helv. Chim. Acta*, 48: 336 (1965). Preferably the compound of formula XV is prepared by cyclizing a compound selected from compounds of the formulas XVI, XVII, XVIII

(Formula set out on pages following Examples) XVI

(Formula set out on pages following Examples) XVII

(Formula set out on pages following Examples) XVIII

and wherein Ph is phenyl and OR¹⁰ and OR¹¹ represent an atom or group removable as an anion whereby
 5 to form a compound of formula XV. The cyclization is advantageously effected under acidic conditions, preferably in the presence of an acid of sulfur or phosphorous, for example, concentrated sulfuric acid or more preferably polyphosphoric acid. The reaction is advantageously carried out at an elevated temperature, preferably at a temperature of from 60 to 120°C, especially from 95 to 105°C, advantageously for about 4-8 hours, preferably about 6 hours.

10 In the compounds of formulae XVII and XVIII R¹⁰ and R¹¹ may, for example, represent hydrogen, (1-6C)alkyl or optionally substituted phenyl. Preferably R¹⁰ represents methyl or ethyl and R¹¹ preferably represents methyl, ethyl or phenyl, but most preferably phenyl.

The compound of formula XVIII may, for example, be obtained by the reaction of 2-amino diphenylsulfide and phenyl chloroformate.

15 The new compound of this invention is a central nervous system depressant and may be used as a tranquilizer for the relief of hyperactivity states, for example, in mice, cats, rats, dogs and other mammalian species, and additionally for the management of psychotic states in man, in the same manner as chlorpromazine. For this purpose a compound of formula II, or non-toxic physiologically acceptable acid addition salts thereof, may be administered orally or parenterally in a conventional dosage form such as tablet, pill, capsule, injectable or the like. The dosage in mg/kg of body weight of a compound of the present invention in mammals will vary according to the size of the animal and particularly with respect to the brain/body weight ratio. In general, a higher mg/kg dosage for a small animal such as dog will have the same effect as a lower mg/kg dosage in an adult human. A minimum effective dosage for a compound of formula II will be at least about 1.0 mg/kg of body weight per day for mammals with a maximum dosage for a small mammal such as a dog, of about 200 mg/kg per day. For humans, a dosage of about 1.0 to 40 mg/kg per day will be effective, for example, about 50 to 200 mg/day for an average person weighing 50 kg. The dosage can be given once daily or in divided doses, for example, 2 to 4 doses daily, and such will depend on the duration and maximum level of activity of a particular compound. The dose may be conventionally formulated in an oral or parenteral dosage form by compounding about 25 to 500 mg per unit of dosage of conventional vehicle, excipient, binder, preservative, stabilizer, flavor or the like as called for by accepted pharmaceutical practice, for example, as described in U.S. Patent 3,755,340. The compound of this invention may be used in pharmaceutical compositions comprising a compound of formula II as previously described or be contained in or co-administered with one or more known drugs.

No overt toxicity has been observed for the compound of formula II and its pharmaceutically acceptable salts when administered at therapeutic doses as hereinbefore described.

Example 1

11-(4-[2-(2-Hydroxyethoxy)ethyl]-1-piperanzinyl]-dibenzo[b,f][1,4]thiazepine (Formula II)

40 A 2 liter round-bottom flask equipped with a magnetic stirring bar and reflux condenser with a nitrogen inlet was charged with 115.0 grams (g) (0.506 mole) of dibenzo[b,f][1,4]thiazepine-11(10H)-one (made by the method disclosed by J. Schmutz et al. *Helv. Chim. Acta*, 48: 336 (1965)), phosphorous oxychloride 700 ml (7.5 moles) and N,N-dimethylaniline 38.0 g (0.313 mole). The grey suspension was heated to gentle refluxing using a heating mantle. After 6 hours of heating, the resulting amber solution was allowed to cool to room temperature (from about 18°-25°C) and was analyzed by thin-layer chromatography (TLC) using silica gel plates, developed with ether-hexane (1:1) and detected with ultraviolet light. Analysis revealed the desired imino chloride, R_f=0.70, and an absence of starting lactam.

45 Excess phosphorous oxychloride, was removed *in vacuo* using a rotary evaporator. The brown syrupy residue was dissolved in 1500 milliliters (ml) of toluene, treated with 500 ml of an ice-water mixture and stirred for 30 minutes. The toluene layer was separated, washed twice with 200 ml of water and dried with anhydrous magnesium sulfate. After removal of the drying agent by filtration, the filtrate was concentrated *in vacuo* using a rotary evaporator to give the crude imino chloride as a light yellow solid: 115.15 g (92.6% yield); melting point (mp) 106-108°.

55 The above imino chloride, 114.0 g (0.464 mole), and 1000 ml of xylene were placed in a 3 liter 3-necked round bottom flask equipped with a mechanical stirrer, reflux condenser with a nitrogen inlet and a heating mantle. The resulting yellow solution was treated with 161.7 g (0.928 mole) of 1-(2-hydroxyethoxy)ethylpiperazine, rinsing with 200 ml of xylene. This reaction mixture was heated at gentle reflux for 30 hours during which time a brown oil began to separate. The reaction mixture was cooled to room temperature. Thin layer chromatography (TLC) analysis (silica gel, methanol: methylene chloride (1:9), ultraviolet light and iodine detection) indicated complete consumption of the imino chloride and the presence of the desired product with R_f=0.5 (approximately). The mixture was treated with 700 ml of 1 Normal (1N) sodium hydroxide and 700 ml of diethyl ether. The layers were separated and the aqueous phase was extracted once with 500 ml of diethyl ether. The combined ether extract was treated with 400 ml of 1N hy-

5 drochloric acid. The acidic extract was treated with solid sodium carbonate portionwise to give a brown oil which was extracted four times with 400 ml of methylene chloride. These methylene chloride extracts were combined and dried with anhydrous magnesium sulfate. The drying agent was removed by filtration and the filtrate was concentrated *in vacuo* using a rotary evaporator to yield the crude product as a viscous amber oil, 194.5 g, which was purified by flask chromatography as follows:

10 The crude product in a minimum of methylene chloride was applied to a 3.5 inch x 20 inch column of silica gel packed in methylene chloride. The column was eluted under nitrogen pressure with 4 liter portions each of methylene chloride, and 2%, 4% and 6% methanol:methylene chloride (2:98; 4:96; 6:94 respectively) while 250 ml fractions were collected. These fractions were monitored by TLC (conditions cited below). The title product began to elute with 4% methanol:methylene chloride (4:96). Combination of the pure fractions and removal of the solvent *in vacuo* gave the title product 138.7 g (77.7% yield). TLC using silica gel, methanol:methylene chloride (1:9) with ultraviolet (u.v.) and iodine detection showed a single compound; R_f =0.5.

15 Analysis calculated for:
 $C_{21}H_{25}N_3O_2S$: C, 65.77; H, 6.57; N, 10.75
 Found: C, 65.25; H, 6.52; N, 10.62

Example 2

20 11-(4-[2-(2-Hydroxyethoxy)ethyl]-1-piperazinyl)dibenzo[b,f][1,4]thiazepine, hydrochloride salt

25 A portion of a product made by the method of Example 1, 10.0 g (26 millimoles (mmol)), was dissolved in 40 ml of ethanol, treated with 30 ml of a saturated ethanolic hydrogen chloride solution and stirred until a turbidity ensued (about 20 minutes). The heterogeneous solution was then added to 500 ml of diethyl ether with stirring. The resulting white crystalline salt was collected by filtration, washed with diethyl ether and dried *in vacuo* in a drying pistol over refluxing ethanol to give the title compound, 10.7 g, m.p. 218-219°.

30 Analysis calculated for:
 $C_{21}H_{25}N_3O_2S.2HCl$: C, 55.26; H, 5.96; N, 9.20
 Found: C, 55.17; H, 6.00; N, 9.07

Example 3

35 11-(4-[2-(2-Hydroxyethoxy)ethyl]-1-piperazinyl)dibenzo[b,f][1,4]thiazepine, maleate

40 A portion of a product made by the method of Example 1, 3.6 g (9.38 mmol), was dissolved in 25 ml of ethanol and treated with 1.08 g (9.38 mmol) of maleic acid. This mixture was heated with stirring until solution was complete and left to cool to room temperature. Addition of diethyl ether resulted in a precipitate which was collected by filtration, washed with diethyl ether and dried *in vacuo* in a drying pistol over refluxing ethanol to give the title compound, 4.2 g, m.p. 129-130°.

45 Analysis calculated for:
 $C_{21}H_{25}N_3O_2S.C_4H_4O_4$: C, 60.10; H, 5.85; N, 8.41
 Found: C, 60.08; H, 5.85; N, 8.36

Example 4

11-(4-[2-(2-Hydroxyethoxy)ethyl]-1-piperazinyl)dibenzo[b,f][1,4]thiazepine, hemifumarate

50 A portion of a product made by the method of Example 1, 2.1 g (5.47 mmol) was dissolved in 20 ml of ethanol and treated with 0.67 g (5.7 mmol) of fumaric acid. Upon heating, complete solution was effected for a few minutes after which the salt began to crystallize. After one hour at room temperature, the resulting solid was collected by filtration and dried *in vacuo* in a drying pistol over refluxing ethanol to give the title compound, 2.4 g, m.p. 172-173°.

55 Analysis calculated for:
 $C_{21}H_{25}N_3O_2S.0.5C_4H_4O_4$: C, 62.57; H, 6.16; N, 9.51
 Found: C, 62.15; H, 6.19; N, 9.25

Examples 5-8

60 A number of tests are recognized as showing antidopaminergic activity of a compound and/or as being predictive of antipsychotic activity in mammals. For these tests a compound of formula II in the form of a salt (for example, as described in Example 2) was used. All dosages in the tables are expressed as free base.

Example 5.Apomorphine-Induced Climbing in Mice

5 This test has been described by Ther and Schramm [*Arch int. Pharmacodyn.*, **138**: 302 (1962); Peuch, Simon and Boissier, *Eur. J. Pharm.*, **50**: 291 (1978)]. Mice that are administered an appropriate dose of apomorphine (a dopamine agonist) will climb the walls of a cage or other suitable structure and remain at or near the top for 20-30 minutes. Untreated mice on the other hand will occasionally climb up and then climb down. The exaggerated climbing of the apomorphine-treated mice can be antagonized by pretreatment with dopamine blocking agents. The antagonism of apomorphine-induced climbing in mice is therefore an indication of the potential dopamine-blocking activity of the agent. Since dopamine blocking agents are typically antipsychotic agents, the test is considered to be evidence for potential antipsychotic activity of the agent. The vehicle itself [hydroxypropylmethylcellulose (HPMC) .5% w/v, polyoxyethylene (20) sorbitan monoleate (Tween 80) .1% w/v, and distilled water] or the vehicle with the test compound of the present invention was administered orally to twenty mice in graded doses. After 30 minutes, apomorphine HCl was administered subcutaneously at 1.25 mg/kg and the mice were placed in cages containing 28 horizontal rungs, upon which the mice could climb. Thirteen minutes later they were scored for climbing. The climbing score was the mean of the highest and lowest rungs on which the mouse climbed during a one-minute time period from 13 to 14 minutes after apomorphine. The results in 24-hour fasted mice are presented in Table 1. The compound of the present invention antagonized the climbing, a result predictive of antipsychotic activity.

Table 1

25	<u>Compound Tested</u>	<u>Dosages (mg/kg i.p.)</u>	<u>Mean Climb Score</u>
30	Vehicle	-	24
	Formula II (HCl salt)	10	24
	Formula II (HCl salt)	20	15
35	Formula II (HCl salt)	40	2
	Formula II (HCl salt)	80	0

Example 6Antagonism of Apomorphine-Induced Hyperactivity in Rats

40 This test has been described by Swerdlow and Koob [*Pharmacol. Biochem. and Behav.*, **23**: 303 (1985)]. Rats that are administered amphetamine at a moderate dose become hyperactive. The hyperactivity can last for several hours, and can be measured in various ways, for example, by counting the number of times the rat walks from one end of a long alley to the other end. The physiological basis for amphetamine-induced hyperactivity is thought to be the release of excessive amounts of dopamine in the brain. The hyperactivity of amphetamine-treated rats can be antagonized (prevented) by pretreatment with dopamine-blocking agents. The antagonism of amphetamine-induced hyperactivity in rats is, therefore, an indication of the potential dopamine-blocking and potential anti-psychotic activity of the agent. The compound of the present invention as the HCl salt or the vehicle (vehicle is defined in Example 5) were administered orally to 20 rats and amphetamine was then injected intraperitoneally. Activity (walking back and forth in a long alley) was recorded for two hours. The activity scores are presented in Table 2. The compound of the present invention antagonized the hyperactivity, a result predictive of antipsychotic activity.

60

65

Table 2

5 Antagonism of Amphetamine-Induced Hyperactivity
in Rats

10	<u>Compound Tested</u>	<u>Dosages (mg/kg p.o.)</u>	<u>Activity Score (0-2 Hr) (Mean Number of Crossings of Center Line of Alley)</u>	
15	Vehicle		148	
20	Formula II (HCl salt)	10	118.3	p < .05
	Formula II (HCl salt)	20	92.4	p < .0005
	Formula II (HCl salt)	40	64.3	p < .0005
	Formula II (HCl salt)	80	39.8	p < .0005

25 Example 7Effect of Test Compound on Rat Striatal Levels of Dihydroxyphenylacetic Acid (DOPAC) and Homovanillic Acid (HVA)

30 Among the various pharmacological effects of antipsychotics, their action as dopamine antagonists in the brain has been extensively investigated. Enhancement of dopamine metabolism (dihydroxyphenylacetic acid and homovanillic acid (DOPAC and HVA)) by antipsychotic agents has been attributed to a blockade of dopamine receptors [A. Carlson and M. Lindquist, *Acta Pharmac. Tox.*, (1963) **20**: 140]. The effects of a compound of the invention on DOPAC and HVA levels in the rat striatum were measured by HPLC using electrochemical detection according to the method of Saller and Salama [*J. Chromatography*, (1984) **309**: 287]. A compound of Formula II (HCl salt) was suspended in the vehicle (as defined in Example 5) and administered intraperitoneally (i.p.) to eight Sprague Dawley rats with the following results.

40	<u>Compound Tested</u>	<u>Dosages (mg/kg i.p.)</u>	<u>% Control</u>	
			<u>DOPAC</u>	<u>HVA</u>
45	Formula II (HCl salt)	10	145	140
	Formula II (HCl salt)	20	220	210
	Formula II (HCl salt)	40	300	260

50 Example 8Conditioned Avoidance in Squirrel Monkeys

55 The conditioned avoidance test has been described by Herz, A., *Int. Rev. Neurobiol.*, (1960) **2**: 229-277. In this test, a warning stimulus is presented for five seconds. The monkeys are trained to press a lever to turn off the warning stimulus thereby avoiding the delivery of electric shocks at 1/sec for 10 seconds that would begin at the end of the warning stimulus. If there is no response during the warning stimulus (no avoidance response) and the shocks begins, a response during the shocks stops the shocks. Trials of this type are repeated every minute for six hours. Antipsychotic drugs produce a marked reduction in responding to the warning stimulus. A compound of the present invention Formula II (HCl salt) was administered orally and the conditioned avoidance test was administered. The vehicle used was that defined in Example 5. The results are presented in Table 3. The compound of the present invention produced a marked reduction of avoidance responses, a result predictive of antipsychotic activity.

Table 3

Conditioned Avoidance in Squirrel Monkeys

		Number of Monkeys Scoring 75% (Or Less) Avoidance Responses/Number Tested	
10	<u>Compound Tested</u>	<u>Dosages (mg/kg p.o.)</u>	<u>Responses/Number Tested</u>
15	Vehicle	-	0/20
	Formula II (HCl salt)	5	0/4
	Formula II (HCl salt)	10	15/20
	Formula II (HCl salt)	20	19/20

Example 9

Test for Production of Acute Dystonia, Acute Dyskinesia, and Tardive Dyskinesia

23 One test for predicting whether or not a potential antipsychotic drug will produce involuntary move-
ments of the type described in this application, such as acute dystonia and acute dyskinesia, is in hal-
operidol-sensitized and drug-naive cebus monkey. Such tests are described by Barany, Haggstrom
30 and Gunne, Acta Pharmacol. et Toxicol., (1983) 52:86; J. Liebment and R. Neale, Psychopharmacology,
(1980), 68:25-29; and B. Weiss and S. Santelli, Science, (1978), 200:799-801. (Also see a discussion of
test results in A. Gunne and S. Barany Psychopharmacology, (1979), 63:195-198. Also, antipsychotic
drugs that are known to produce tardive dyskinesia in schizophrenic patients produce acute dyskinetic
35 and dystonic reactions in the haloperidol-sensitized cebus monkey. Clozapine, the only antipsychotic
drug for which there has been no tardive dyskinesia reported, does not produce a dyskinetic reaction in
sensitized cebus monkeys. The compound of Formula II, clozapine, thioridazine or haloperidol were each
40 orally administered to sensitized cebus monkeys. There were then observed in their home cages continu-
ously for eight hours and occurrences of dyskinetic reactions noted. The results are presented in Table
4. The compound of the present invention exhibited markedly fewer dyskinetic and dystonic reactions as
45 compared to the known dyskinetic drugs haloperidol or thioridazine. In addition to producing fewer reac-
tions, the intensity of the reactions produced by the compound of the present invention was less than
that of thioridazine or haloperidol. For example, at 20 mg/kg p.o. the compound of the present invention
produced reactions in two of thirteen monkeys; however, one of these reactions was extremely weak,
lasting only about five minutes. The reaction at 10 mg/kg was also weak, lasting only about twenty sec-
45 onds. By contrast, the reactions produced by thioridazine or haloperidol typically lasted several hours
and were of moderate or high intensity.

50

55

60

65

Table 4

Dyskinetic Reactions in Sensitized Cebus Monkeys

5	<u>Compound Tested</u>	<u>Dosages (mg/kg p.o.)</u>	<u>Number of Monkeys with Dyskinetic Reactions/Number Tested</u>
10	Haloperidol	1.0	13/13
15	Thioridazine	10	11/13
20	Clozapine	10	0/1
25	Clozapine	20	0/13
30	Clozapine	40	0/11
35	Clozapine	60	0/5
40	Formula II (HCl salt)	2.5	0/13
45	Formula II (HCl salt)	5	1/13
50	Formula II (HCl salt)	10	1/13
55	Formula II (HCl salt)	20	2/13
60	Formula II (HCl salt)	40	0/4

Example 10

(a) 11-[4-[2-(2-Hydroxyethoxy)ethyl]-1-piperazinyl]-dibenzo[b,f][1,4]thiazepine. (Formula II)

35 11-Piperazinyl-dibenzo[b,f][1,4]thiazepine dihydrochloride (25 mmole), sodium carbonate (150 mmole), sodium iodide (1 mmole) and 2-chloroethoxyethanol (27 mmoles) were combined together in n-propanol (60 ml) and N-methyl pyrrolidone (15 ml). The reaction was heated at reflux for 24 hours. Ethyl acetate (75 ml) was added and the reaction washed with water (2 x 250 ml). The organic phase was dried over magnesium sulfate and the solvent removed in vacuo to give an oil. The oil was dissolved in ethanol and treated with fumaric acid (14 mmole). The product was isolated as the hemi-fumarate salt in 78% yield, melting point (m.p.) 172-173°.

40 The thiazepine derivative used as a starting material was prepared as follows:

(b) 11-Piperazinyl-dibenzo[b,f][1,4]thiazepine.

45 Piperazine (1.7 mole) was dissolved in warm toluene (about 50°C) (750 ml) and 11-chloro-dibenzo[b,f][1,4]thiazepine was added. The reaction was heated to reflux and maintained at this temperature for 5 hours. After cooling to ambient temperature the reaction was filtered to remove piperazine hydrochloride, and the organic phase was washed several times with water to remove excess piperazine. The 50 organic phase was dried over magnesium sulfate and after filtration the solvent was removed in vacuo to give the product as an oil. The oil was dissolved in ethanol and treated with a solution of hydrogen chloride in ethanol.

55 11-Piperazinyl-dibenzo[b,f][1,4]thiazepine was isolated as the dihydrochloride salt in about 88% yield.

(c) 11-Chloro-dibenzo[b,f][1,4]thiazepine

60 A 2 liter round-bottom flask equipped with a magnetic stirring bar and reflux condenser with a nitrogen inlet was charged with 115.0 g (0.506 mole) of dibenzo[b,f][1,4]thiazepine-11(10-H)one, phosphorous oxychloride 700 ml (7.5 moles) and N,N-dimethylaniline 38.0 g (0.313 mole). The grey suspension was heated to gentle refluxing using a heating mantle. After 6 hours of heating, the resulting amber solution was allowed to cool to room temperature (from about 18°-25°C) and was analyzed by thin-layer chromatography (TLC) using silica gel plates, developed with ether-hexane (1:1) and detected with ultraviolet light. Analysis revealed the desired imino chloride, $R_f=0.70$, and an absence of starting lactam.

65 Excess phosphorous oxychloride, was removed in vacuo using a rotary evaporator. The brown syrupy residue was dissolved in 1500 milliliters (ml) of toluene, treated with 500 ml of an ice-water mixture and

stirred for 30 minutes. The toluene layer was separated, washed twice with 200 ml of water and dried with anhydrous magnesium sulfate. After removal of the drying agent by filtration, the filtrate was concentrated *in vacuo* using a rotary evaporator to give the crude imino chloride as a light yellow solid; 115.15 g (92.6% yield); m.p. 106-108°.

5 (d) Dibenzo[b,f][1,4]thiazepine-11-(10H)one.

10 Polyphosphoric acid (1.2 mole) was heated at 65°C and phenyl 2-(phenylthio-phenyl)carbamate (0.16 mole) added with stirring. The reaction was heated to 100°C ±5°C and maintained at this temperature for 6 hours. The reaction was cooled to about 80°C and water (1.5 liters) was added slowly. After cooling to ambient temperature the product was filtered off as an off-white solid, washed sparingly with acetone and dried. The yield was about 87%.

15 (e) Phenyl 2-(phenylthio)-phenylcarbamate.

20 2-Amino diphenylsulfide (0.4 mole) was dissolved in toluene (500 ml) and cooled to 5°C. Phenyl chloroformate (0.24 mole) in toluene (50 ml) was added slowly to the stirred solution over 1 hour. When addition was complete a simultaneous addition of phenyl chloroformate (0.24 mole) in toluene (50 ml) and an aqueous solution of sodium hydroxide (0.3 mole) and sodium carbonate (0.35 mole) (200 ml) was started.

25 After completing the addition, the reaction was stirred for 1 hour. The aqueous phase was discarded and the organic phase was washed with dilute hydrochloric acid. The organic phase was dried over magnesium sulfate. After filtration the toluene was removed *in vacuo*. Recrystallization of the residue from hexane afforded the urethane in about 90% yield.

25 **EXAMPLE A**

Tablets:

Each tablet contains:

Compound of formula II	5 mg
Lactose	88 mg
Magnesium stearate	1 mg
Polyvinylpyrrolidone	2 mg
Sodium starch glycolate	4 mg

30 The compound of formula II, lactose, and a portion of the sodium starch glycolate and the polyvinylpyrrolidone are mixed in a suitable mixer and water added until the desired mass for granulation is obtained. The mass obtained may be passed through a suitable size mesh and dried to obtain the optimum moisture content. The remaining sodium starch glycolate and magnesium stearate is then added and the dry granulate is then passed through a further screen before final blending and compression to yield tablets each weighing 100 mg.

40 **EXAMPLE B**

Tablets:

Each tablet contains:

Compound of formula II	250 mg
Lactose	122 mg
Magnesium stearate	4 mg
Pregelatinized Starch	8 mg
Sodium starch glycolate	16 mg

50 The tablets are formulated as described in Example A to yield tablets each weighing 600 mg. The pre-gelatinized starch replaces the polyvinylpyrrolidone.


EXAMPLE C

55 Tablets:

Each tablet contains:

Compound of formula II	100 mg
Lactose	84 mg
Stearic Acid	4 mg
Pregelatinized starch	4 mg
Starch (maize)	8 mg


60 The tablets are formulated as described in Example A to yield tablets each weighing 200 mg. The stearic acid pregelatinized starch and starch (maize) replace the magnesium stearate, polyvinylpyrrolidone and sodium starch glycolate.



I

15

20



Ia

25

30

35

40


45

50


55

60


65



II




III



10

15



25

30

35

40


45

50


55

60


65



VI



VII



XIII



XIII

10

15

20

25

30

35

40


45

50


55

60


65




XIV



XV




XVI



XVII

5



XVIII


10 Claims for the Contracting States: BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. A compound of formula II:

15



20



II

25

or a salt thereof.


30 2. A compound as claimed in claim 1 in the form of a pharmaceutically acceptable salt.
 3. A compound as claimed in claim 1 in the form of the hemifumarate salt.
 4. A compound as claimed in claim 1 in the form of the hydrochloride salt.
 5. A process for the preparation of a compound as defined in claim 1 selected from:

(a) reacting an imino chloride of formula IV:

35



40




IV

45

with 1-hydroxyethoxyethyl piperazine; and
 (b) reacting a thioether of formula VII:

50




VII

55

with a piperazine of formula V:

60




V

65

and, whereafter when the compound of formula II is obtained as a base and a salt is required, reacting said compound of formula II obtained in the form of a base with an acid to afford a salt and when the compound of formula II is obtained as a salt and a base is required, neutralising said compound of formula II obtained in the form of a salt to afford the said base.

5 2. A pharmaceutical composition comprising as active ingredient at least one compound of formula II:




or a pharmaceutically acceptable salt thereof in association with a non-toxic pharmaceutically acceptable carrier or excipient.

25 7. A compound of formula II, or a pharmaceutically acceptable salt thereof, for use in the management of psychotic states in man.

8. The use of a compound of formula II, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the management of psychotic states in man.


30 **Claims for the Contracting States: AT, ES, GR**

35 1. A process for the preparation of a compound of formula II, or a salt thereof:




selected from:

(a) reacting an imino chloride of formula IV:




60 with 1-hydroxyethoxyethyl piperazine; and
(b) reacting a thioether of formula VII:

65




10 with a piperazine of formula V:



20 and, whereafter when the compound of formula II is obtained as a base and a salt is required, reacting said compound of formula II obtained in the form of a base with an acid to afford a salt and when the compound of formula II is obtained as a salt and a base is required, neutralising said compound of formula II obtained in the form of a salt to afford the said base.


25 Patentansprüche für die Vertragsstaaten: BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. Verbindung der Formel II




oder ein Salz davon.

2. Verbindung nach Anspruch 1 in Form eines pharmazeutisch zulässigen Salzes.
 3. Verbindung nach Anspruch 1 in Form des Hemifumarat-Salzes.
 4. Verbindung nach Anspruch 1 in Form des Hydrochlorid-Salzes.
 5. Verfahren zur Herstellung einer Verbindung nach Anspruch 1, bei welchem
 (a) ein Iminochlorid der Formel IV



60 mit 1-Hydroxyethoxyethyl-piperazin umgesetzt wird oder
 (b) ein Thioether der Formel VII




VII

10 mit einem Piperazin der Formel V



20 umgesetzt wird,
worauf, wenn die Verbindung der Formel II als Base erhalten wird und ein Salz gewünscht wird, die in
Form der Base erhaltene Verbindung der Formel II zur Bildung eines Salzes mit einer Säure umgesetzt
wird und, wenn die Verbindung der Formel II als Salz erhalten wird und eine Base gewünscht wird,
die in Form des Salzes erhaltene Verbindung der Formel II zur Bildung einer Base neutralisiert wird.

25 6. Pharmazeutische Zusammensetzung, welche als aktiven Bestandteil mindestens eine Verbindung
der Formel II



oder ein pharmazeutisch zulässiges Salz davon gemeinsam mit einem nichtgiftigen, pharmazeutisch zu-
lässigen Träger oder Exziopiens enthält.


7. Verbindung der Formel II oder ein pharmazeutisch zulässiges Salz davon für die Verwendung bei
der Behandlung von psychotischen Zuständen beim Menschen.

8. Die Verwendung einer Verbindung der Formel II oder eines pharmazeutisch zulässigen Salzes da-
von bei der Herstellung eines Medikaments für die Behandlung von psychotischen Zuständen beim
Menschen.

Patentansprüche für die Vertragsstaaten: AT, ES, GR

1. Verfahren zur Herstellung einer Verbindung der Formel II

5



II

10

15

20

25

30

35

40


45

50


55

60

65


oder eines Salzes davon, bei welchem
(a) ein Iminochlorid der Formel IV

IV

mit 1-Hydroxyethoxyethyl-piperazin umgesetzt wird oder
(b) ein Thioether der Formel VII

VII

mit einem Piperazin der Formel V



V

umgesetzt wird,
worauf, wenn die Verbindung der Formel II als Base erhalten wird und ein Salz gewünscht wird, die in Form der Base erhaltene Verbindung der Formel II zur Bildung eines Salzes mit einer Säure umgesetzt wird und, wenn die Verbindung der Formel II als Salz erhalten wird und eine Base gewünscht wird, die in Form des Salzes erhaltene Verbindung der Formel II zur Bildung einer Base neutralisiert wird.

Revendications pour les Etats Contractants: BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. Composé de formule II:

5

10

15

20 ou un de ses sels.

2. Composé suivant la revendication 1, sous forme d'un sel pharmaceutiquement acceptable.

3. Composé suivant la revendication 1, sous forme d'hémifumarate.

4. Composé suivant la revendication 1, sous forme de chlorhydrate.

25 5. Procédé de préparation d'un composé suivant la revendication 1, choisi entre:
(a) la réaction d'un imino-chlorure de formule IV:

30

35

avec la 1-hydroxyéthoxyéthylpipérazine; et
(b) la réaction d'un thioéther de formule VII:

40

45


50 avec une pipérazine de formule V:

55


60

puis, lorsque le composé de formule II est obtenu sous forme d'une base et qu'un sel est requis, la réaction dudit composé de formule II, obtenu sous forme de base, avec un acide pour donner un sel, et, lorsque le composé de formule II est obtenu sous forme d'un sel et qu'une base est requise, la neutralisation dudit composé de formule II, obtenu sous forme de sel, pour donner ladite base.


65 6. Composition pharmaceutique comprenant comme ingrédient actif au moins un composé de formule II:




II




IV



VII



V




ou un de ses sels pharmaceutiquement acceptables, en association avec un support ou excipient non toxique, pharmaceutiquement acceptable.

7. Composé de formule II, ou un de ses sels pharmaceutiquement acceptables, destiné à être utilisé dans le traitement d'états psychotiques chez l'homme.

8. Utilisation d'un composé de formule II, ou d'un de ses sels pharmaceutiquement acceptables, dans la production d'un médicament destiné au traitement d'états psychotiques chez l'homme.


Revendications pour les Etats Contractants: AT, ES, GR

1. Procédé de préparation d'un composé de formule II, ou d'un de ses sels:




choisi entre:

(a) la réaction d'un imino-chlorure de formule IV:




avec la 1-hydroxyéthoxyéthylpipérazine; et

(b) la réaction d'un thioéther de formule VII:



avec une pipérazine de formule V:

5



V

10 puis, lorsque le composé de formule II est obtenu sous forme d'une base et qu'un sel est requis, la réaction dudit composé de formule II, obtenu sous forme de base, avec un acide pour donner un sel, et, lorsque le composé de formule II est obtenu sous forme d'un sel et qu'une base est requise, la neutralisation dudit composé de formule II, obtenu sous forme de sel, pour donner ladite base.

15

20

25

30

35

40

45

50

55

60

65